Grufity logoGrufity logo

CDNA

12.79USD+0.08(+0.63%)Market Closed

CareDx Inc

Market Summary

USD12.79+0.08Market Closed
0.63%

CDNA Stock Price

RSI Chart

Valuation

Market Cap

1.1B

Price/Earnings

-15.26

Price/Sales

3.36

Price/Cashflow

-50.92

MarketCap/EBT

-15.02

Price/Sales

Profitability

Operating Margin

82.58%

EBT Margin

-22.40%

Return on Equity

-15.64%

Return on Assets

-12.82%

Fundamentals

Revenue

Revenue (TTM)

314.9M

Revenue Y/Y

8.69%

Revenue Q/Q

1.53%

Earnings

Earnings (TTM)

-69.4M

Earnings Y/Y

-1.0K%

Earnings Q/Q

-10.43%

Price Action

52 Week Range

11.9247.82
(Low)(High)

Last 7 days

-6.8%

Last 30 days

-26.5%

Last 90 days

-42.1%

Trailing 12 Months

-69.6%

Financial Health

Current Ratio

5.15

Debt/Equity

0.02

Debt/Cashflow

-1.89

Investor Care

Shares Dilution (1Y)

1.58%

Diluted EPS (TTM)

-1.32

Peers (Alternatives to CareDx)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
5.63% 39.30%
20.65
4.55
4.80% 77.95%
81.0B
14.2B
-0.24% 13.25%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
1.82% 69.21%
24.61
9.26
22.03% 50.41%
16.6B
3.3B
7.30% 21.86%
17.56
5
22.05% 63.88%
MID-CAP
4.6B
776.0M
-12.75% -61.03%
-8.03
6.39
37.38% -33.90%
3.8B
249.9M
-6.13% -58.53%
-24.67
15.19
132.20% -22.25%
SMALL-CAP
1.4B
268.4M
64.51% -37.76%
-28.41
5.15
70.42% 22.87%
1.1B
314.9M
-26.49% -69.61%
-15.26
3.36
24.16% -675.60%
616.1M
123.7M
3.59% -52.65%
-13.85
5.59
43.31% -77.98%
555.2M
520.0M
36.23% -84.01%
-0.18
1.11
19.60% -686.73%
431.9M
463.2M
-10.16% -72.81%
5.91
0.94
3.79% -0.40%
153.0M
-
-7.37% -37.47%
-4.99
-
- -39.92%
9.1M
3.3M
6.02% -88.13%
-0.36
2.22
-21.77% 4.40%

Financials for CareDx

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue2.1%315308296276254
Operating Expenses6.6%380356326293265
  S&GA Expenses8.7%9285777365
  R&D Expenses4.4%8682776861
Earnings Before Taxes-38.8%-70.52-50.80-32.09-18.72-9.72
Net Income-39.8%-69.39-49.62-30.66-18.03-8.95
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets-1.0%541547567563557
  Current Assets-1.8%404411433445441
    Cash Equivalents-2.9%167172348353336
  Inventory3.6%1918171915
  Net PPE19.4%3328221914
  Goodwill0.3%3737372626
Liabilities9.6%98891019178
  Current Liabilities17.2%7867777056
Shareholder's Equity-3.1%444458466472480
  Retained Earnings-5.4%-424.50-402.80-383.20-367.00-355.14
  Additional Paid-In Capital1.1%875865854843838
Shares Outstanding0.4%5353535353
Float-4,600----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-191.6%-20.80-7.13-19.29-16.28-11.45
  Share Based Compensation8.0%4340363329
Cashflow From Investing-12.1%-142.82-127.4048-34.98-59.42
Cashflow From Financing-87.4%-5.10-2.72186190195

Risks

What is the probability of a big loss on CDNA?

100%


Probability that CareDx stock will be more than 20% underwater in next one year

83.8%


Probability that CareDx stock will be more than 30% underwater in next one year.

45.8%


Probability that CareDx stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does CDNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if CareDx was unfortunately bought at previous high price.

Returns

Cumulative Returns on CDNA

10.1%


7-Year Cumulative Returns

13.7%


5-Year Cumulative Returns

-15.0%


3-Year Cumulative Returns

What are the long-term rolling returns for CDNA?

FIve years rolling returns for CareDx.

Which funds bought or sold CDNA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-1.62
-317,000
1,122,000
-%
2022-11-17
CENTRAL TRUST Co
SOLD OFF
-100
-
-
-%
2022-11-17
Grandeur Peak Global Advisors, LLC
UNCHANGED
-
-84,000
320,000
0.02%
2022-11-17
M&T Bank Corp
ADDED
13.53
-66,000
586,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-186,000
-
-%
2022-11-15
Truvestments Capital LLC
UNCHANGED
-
-1,000
4,000
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
576.75
1,339,950
1,647,110
-%
2022-11-15
ALLIANCEBERNSTEIN L.P.
REDUCED
-0.07
-282,000
1,074,000
-%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
STATE STREET CORP
ADDED
0.74
-18,264,000
72,267,000
-%

1–10 of 48

Latest Funds Activity

Are funds buying CDNA calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own CDNA

CareDx News

Nanalyze

CareDx Stock is Pure Play on Organ Transplant Diagnostics.2 days ago

GuruFocus.com

GuruFocus.com

GuruFocus.com

GuruFocus.com

GuruFocus.com

Thehour.com

CDNA Fair Value

Recent SEC filings of CareDx

View All Filings
Date Filed Form Type Document
Nov 23, 2022
4
Insider Trading
Nov 23, 2022
8-K
Current Report
Nov 08, 2022
4/A
Insider Trading
Nov 07, 2022
4
Insider Trading
Nov 03, 2022
10-Q
Quarterly Report
Nov 03, 2022
8-K
Current Report
Oct 11, 2022
SC 13G/A
Major Ownership Report
Oct 07, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading

Latest Insider Trading transactions for CDNA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-23
Bickerstaff George
ACQUIRED
18,300
1.22
15,000
-
2022-11-02
Seeto Reginald
SOLD FOR TAXES
-18,307.3
19.19
-954
See Remarks
2022-10-06
Ronai Abraham
SOLD FOR TAXES
-44,856
18
-2,492
See Remarks
2022-09-07
Ronai Abraham
ACQUIRED
-
-
12,000
See Remarks
2022-09-07
Jain Abhishek
ACQUIRED
-
-
22,150
Chief Financial Officer
2022-08-11
Maag Peter
SOLD
-493,143
24.6572
-20,000
-
2022-08-10
Colon Grace
SOLD
-62,546
24.81
-2,521
-
2022-08-09
Seeto Reginald
ACQUIRED
-
-
93,912
See Remarks
2022-08-09
Johnson Alexander L
ACQUIRED
-
-
54,768
Chief Business Officer
2022-08-09
King Sasha
ACQUIRED
-
-
31,298
Chief Marketing Officer

1–10 of 50

Reginald Seeto
640
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CDNA Income Statement

2022-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Total revenue$ 79,359$ 75,589$ 239,409$ 217,177
Operating expenses:    
Research and development22,30619,43966,81854,479
Sales and marketing22,26121,37072,35956,421
General and administrative23,83018,67175,62150,216
Total operating expenses96,69884,316297,520231,504
Loss from operations(17,339)(8,727)(58,111)(14,327)
Other income (expense):    
Interest income, net1,225201,892147
Change in estimated fair value of common stock warrant liability14888950
Other expense, net(572)(3,440)(1,948)(906)
Total other income (expense)667(3,332)33(709)
Loss before income taxes(16,672)(12,059)(58,078)(15,036)
Income tax (expense) benefit(267)162(206)525
Net loss$ (16,939)$ (11,897)$ (58,284)$ (14,511)
Net loss per share    
Basic (in dollars per share)$ (0.32)$ (0.23)$ (1.09)$ (0.28)
Diluted (in dollars per share)$ (0.32)$ (0.23)$ (1.09)$ (0.28)
Weighted-average shares used to compute net loss per share:    
Basic (in shares)53,489,41852,681,45153,253,21052,034,450
Diluted (in shares)53,489,41852,681,45153,253,21052,034,450
Testing services revenue    
Revenue:    
Total revenue$ 64,751$ 66,464$ 198,330$ 190,635
Operating expenses:    
Cost of testing services, product, digital, and other17,77118,03853,62951,756
Product revenue    
Revenue:    
Total revenue7,1946,52120,69619,160
Operating expenses:    
Cost of testing services, product, digital, and other4,7364,91913,02213,771
Patient and digital solutions revenue    
Revenue:    
Total revenue7,4142,60420,3837,382
Operating expenses:    
Cost of testing services, product, digital, and other$ 5,794$ 1,879$ 16,071$ 4,861

CDNA Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 82,959$ 348,485
Marketable securities208,3170
Accounts receivable70,42559,761
Inventory18,08617,186
Prepaid and other current assets8,3707,928
Total current assets388,157433,360
Property and equipment, net34,04922,044
Operating leases right-of-use assets35,84317,993
Intangible assets, net43,85550,195
Goodwill37,52336,983
Restricted cash198211
Other assets4,8865,835
Total assets544,511566,621
Current liabilities:  
Accounts payable10,62513,337
Accrued compensation14,31226,042
Accrued and other liabilities45,35137,922
Total current liabilities70,28877,301
Deferred tax liability13415
Common stock warrant liability50139
Deferred payments for intangible assets2,5225,041
Operating lease liability, less current portion34,70817,394
Other liabilities251455
Total liabilities107,832100,745
Commitments and contingencies (Note 9)
Stockholders’ equity:  
Preferred stock: $0.001 par value; 10,000,000 shares authorized at September 30, 2022 and December 31, 2021; no shares issued and outstanding at September 30, 2022 and December 31, 202100
Common stock: $0.001 par value; 100,000,000 shares authorized at September 30, 2022 and December 31, 2021; 53,523,453 shares and 52,923,360 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively5252
Additional paid-in capital886,909853,683
Accumulated other comprehensive loss(8,809)(4,670)
Accumulated deficit(441,473)(383,189)
Total stockholders’ equity436,679465,876
Total liabilities and stockholders’ equity$ 544,511$ 566,621